Human Genome Sciences (NASDAQ:HGSI)

CAPS Rating: 2 out of 5

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Featured Broker Partners


Advertisement